2009, Number 1
<< Back Next >>
Rev Educ Bioquimica 2009; 28 (1)
La homocisteína: un aminoácido neurotóxico
Sánchez CM, Jiménez RSP, Morgado VJS
Language: Spanish
References: 31
Page: 3-8
PDF size: 115.27 Kb.
ABSTRACT
The homocysteine is an aminoacid of great importance
in the cellular metabolism. It has been considered an
atherogenic factor in diverse pathologies, such as
cardiovascular and cerebrovascular illnesses. In the last
years attention has been given to the link of high
homocysteine plasma concentrations and the damage of
neural cells, which has led to many mechanisms of
neurotoxicity of the homocysteine, such as the generation
of reactive oxygen intermediates, pro-thrombotic effects,
oxidative stress, the formation of homocysteine
derivatives, accumulation of the β-amyloid and the
activation of apoptosis among others. In this revision
examples of the mechanisms of neurotoxicity caused by
the homocysteine in Alzheimer, cardiovascular illnesses,
dementia and Parkinson´s disease are presented.
REFERENCES
Mathews CK, van Holde KE, Ahern KG (2002) Bioquímica. Adisson Wesley, Madrid España, p. 1335.
Baynes JW, Dominiczak MH (2005) Medical Biochemistry. Elsevier Mosby. Philadelphia, USA, p. 693.
Sepúlveda SJM, Matía FR, Martínez SA, González de la Aleja TJ, Rodríguez PM, Porta EJ (2004) Homocisteína y enfermedad cerebrovascular. Rev Neurol 38: 347-5.8
Kruman II, Culmsee C, Chan SL, Kruman Y, Guo Z, Penix L, Mattson PM (2000) Homocysteine Elicits a DNA Damage Response in Neurons That Promotes Apoptosis and Hypersensitivity to Excitotoxicity. J Neurosci 20: 6920-6926.
Parra Ol, Estrada GR, Guzmán GMO (2007) La mutación 677 C>T en la 5, 10 metilentetrahidrofolato reductasa y el aumento de homocisteína en pacientes mexicanos con un estado de trombofilia. Med Int Mex. 23: 15-18.
Karine R, Santiard-Baron D, Chassé JF, Paly E, Aupetit J, Kamoun P, London J, Janel N (2004) The neuronal SAPK/JNK pathway is altered in a murine model of hyperhomocysteinemia. J Neurochem 89: 33-43.
Sanchez CM. Un factor aterogénico no convencional: La homocisteína (2001) Bioquimia 26(3): 54-58.
White AR, Huang X, Joblin FM, Barrow JC, Beyreuther K, Masters LC, Bush IA, Cappai R (2001) Homocysteine potentiates copper- and amyloid beta peptide-mediated toxicity in primary neuronal cultures: possible risk factors in the Alzheimer's-type neurodegenerative pathways. J Neurochem 76:1509-1520.
Loscalzo J (2002) Homocysteine and dementias. N Engl J Med 346:466-468.
Ho PI, Collins SC, Dhitavat S, Ortiz D, Ashline D, Rogers E, Shea BT (2001) Homocysteine potentiates β- amyloid neurotoxicity: role of oxidative stress. J Neurochem 77: 1-6.
Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL (2005) Harrison Principios de Medicina Interna. Mc Graw Hill-Interamericana, México D.F, p.3100.
Seshadri S, Beiser A, Selhub J, Jacques FP, Rosenberg HI, D´Agostino B, Wilson WFP, Wolf AP (2002) Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease. N Engl J Med 346 : 476-486.
García VA, Custodio N, Montesinos R (2000) Apoptosis y caspasas en enfermedad de Alzheimer. Rev Per Neurol 6: 24-29.
Korczyn A (2002) Homocysteine, Stroke and Dementia. Stroke 33: 2343-2344.
Cardo E, Pineda M, Vilaseca MA, Artuch R, Campistol J (2000) Risk factors in cerebrovascular disease in childhood. Rev Neurol 30:21-27.
Naess H, Nyland HI, Thomassen L, Aarseth J, Myhr MKL (2004) Etiology of and risk factors for cerebral infarction in young adults in western Norway: a population-based case-control study. Europ J Neurol 11: 25-30.
Rodríguez ML, Serra VI, Álvarez GE (2003) Homocistinemia, factor de riesgo oculto en la enfermedad cerebrovascular isquémica. Presentación de un caso. Rev Cubana Med 42:0-0 .
Fernández MM, Castilla GL, Castella MA, Cueli RB, Fernández BR, Gutiérrez TR, Jiménez GT (2003) Trombosis venosa cerebral en relación con la hiperhomocisteinemia. Rev Neurol 37:1040-1043.
Sánchez MB, Grasa JM (2006) Polimorfismo C677T del gen de la metilentetrahidrofolato reductasa (MTHFR) en la patología isquémica vascular. Rev Neurol 43: 630-636.
Carod- Artal FJ, Nunes SV, Vargas AP, Portugal D (2007) Factores determinantes de la hiperhomocisteinemia en la fase crónica del ictus. Rev Neurol 44:513-519.
Kullo JI, Ding KY, Boerwinkle E, Turner ST, Mosley TH, Kardia SL (2006) Novel Genomic Loci Influencing Plasma Homocysteine Levels. Stroke 37:1703-1709.
Amos DK (2002) Homocysteine, stroke, and dementia. Stroke 33:2343-2344.
Hassan A, Hunt BJ, O'Sullivan M, Bell R, D´ Souza R, Jeffery S, Bamford MJ, Markus SH (2004) Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain 127: 212 - 219.
Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM (1998) Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 55:1449-1455.
Clarke R (2006) Vitamin B 12, Folic Acid, and the Prevention of Dementia. N Engl J Med 354: 2817-2818.
Robinson G, Narasimhan S, Weatherall M, Beasley R (2005) Raised plasma homocysteine levels in alcoholism: increasing the risk of heart disease and dementia? J New Zealand Med Assoc 118:24-30.
Zhang J, Kravtsov V, Amarnath V, Picklo JM, Graham GD, Montine JT (2000) Enhancement of dopaminergic neurotoxity by the mercapturate of dopamine: relevante to Parkinson`s disease. J Neurochem 74: 970-978.
Martínez LE, Martínez HR, Del Roble VM, Sampallo E, Aguirre RA, González HC, Cantú LA, Garza NL, Rivas MA (2003) Niveles séricos de homocisteína en enfermedad de Parkinson. Rev Mex Neuroci 4: 413-418.
Rivas MA, Martínez LE, Martínez HR, Del Roble VM, González HC, Cantú ML, Sampallo E, Aguirre RA 2003) Niveles séricos de homocisteína en enfermedad de Parkinson. Rev Mex Neuroci 4: 429.
Duan W, Ladenheim B, Cutler GR, Kruman II, Cadet JL, Mattson PM (2002) Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson`s disease. J Neurochem 80: 101-110.
O'Suilleabhain PE, Sung V, Hernandez C, Lacritz L, Dewey BR, Bottiglieri T, Díaz -Arrastia R (2007) Elevated Plasma Homocysteine Level in Patients With Parkinson Disease. Arch Neurol 61: 865-868.
Full text